Drylab AI Research Platform

Drylab is a startup founded in 2025 by a Vietnamese founding team (CEO John Phan, CSO Nhi Nguyen) that builds AI agents for computational research in life sciences. Press coverage describes operations in Singapore and San Francisco. The company targets the slow, manual analysis of omics and clinical data in biotech and pharma R&D.

The platform plans analyses, generates code and runs them in one click on multimodal data such as genomics, transcriptomics, proteomics, imaging and clinical data. Agents draw on 800+ integrated scientific tools and databases, and a verification model checks analytical decisions. A desktop app keeps data on the user's machine, and API and MCP access allow programmatic runs. Customers include pharma companies, cancer centres, research institutes and universities.

• Data analysis agents: plan, generate code and run analyses in one click.
• Multimodal data support: genomics, transcriptomics, proteomics, epigenomics, metabolomics, imaging and clinical data.
• Use cases: biomarker discovery and patient stratification and prediction.
• Review and batch tools: human-in-the-loop review gates, batch processing and sandboxes on demand.
• Desktop app and Vault: local data processing plus encrypted storage with multi-factor authentication.
• API and MCP: programmatic runs and integration with other AI tools.

Vietnamese universities and research institutes can use it to analyse genomic cohorts faster. Pharmaceutical and diagnostics companies in Vietnam can apply it to biomarker discovery. Hospitals with research units can use the desktop app to analyse clinical data without moving it off-site.

Automates routine computational analysis so lean biotech teams can test hypotheses faster. Human-in-the-loop review gates and a verification model help catch methodological errors. Data can stay on the user's machine or on private infrastructure for sensitive projects. A free one-month trial of the web app lowers the cost of evaluation.

Pharma and biotech teams generate far more omics data than analysts can process, driving demand for AI agents in R&D. Funding for agentic AI in Southeast Asia is rising, and Vietnamese-founded teams are entering global life-science AI. Vietnam's growing genomics and clinical research sector is a potential local market.

Founded 2025. Seed round of USD 3 million announced in October 2026, led by Vertex Ventures Southeast Asia & India with PatSnap participating. Commercial launch in February 2026. Funds go to enterprise sales, engineering and security certifications.